Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- ChecktodayChange DetectedUpdated from v3.0.1 to v3.0.2; removed the 'Back to Top' element. No other substantive changes detected.SummaryDifference0.2%
- Check7 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check15 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new medical topics related to bladder cancer and urologic diseases. Notably, the version has been updated from v2.16.12 to v3.0.0.SummaryDifference4%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.